Skip to main content

Table 2 Clinical outcomes after filter insertion

From: Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study

  Rivaroxaban group Warfarin group P value
Filter complications
 Symptomatic filter thrombosis 4(3.5%) 5(5.7%) 0.690
  TrapEase filter 0 2  
  OptEase filter 3 1  
  G2 filter 0 1  
  Aegisy filter 1 1  
 Other complications 2(1.8%) 2(2.3%) 1.000
Time to symptomatic filter thrombosis
 Mean days (SD) 439.3(214.9) 369.8(245.3) 0.624
 Median 462.0 308.0  
 Q1, Q3 223.8, 632.0 164.5, 606.0  
Recurrent VTE
 Total 2(1.8%) 4(4.6%) 0.407
 DVT 2(1.8%) 3(3.4%) 0.655
 PE 1(1.1%)  
Deaths
 Total 9(7.9%) 8(9.1%) 0.761
 VTE-related 0 1(1.1%)  
 Cancer-related 5(4.4%) 4(4.5%) 1.000
 Others 4(3.5%) 3(3.4%) 1.000
Safety outcomes
 Total 5(4.4%) 14(15.9%) 0.005
 Major bleeding 1(0.9%) 2(2.3%) 0.581
 CRNM bleeding 4(3.5%) 12(13.6%) 0.008